Polarean Imaging Company Description
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States.
The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform.
It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag.
Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.

Country | United Kingdom |
Founded | 2016 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 26 |
CEO | Christopher Von Jako |
Contact Details
Address: 27-28 Eastcastle Street London, W1W 8DH United Kingdom | |
Website | polarean.com |
Stock Details
Ticker Symbol | PLLWF |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
ISIN Number | GB00BF3DT583 |
SIC Code | 3821 |
Key Executives
Name | Position |
---|---|
Dr. Christopher Richard Von Jako Ph.D. | Chief Executive Officer and Director |
Dr. Kenneth Paul West Ph.D. | Non-Executive Chairman of the Board |
Charles Fremont Osborne Jr. | Chief Financial Officer and Director |
Neil Wadehra | Vice President of Operations |
Alex Dusek | Chief Commercial Officer |
Dr. Chase Hall M.D. | Chief Medical Advisor |
Stephen Austin | Company Secretary |